Cystic Fibrosis-Drug Pipeline Analysis and Market Forecasts to 2015

Oct. 8, 2010 - PRLog -- "Cystic Fibrosis-Drug Pipeline Analysis and Market Forecasts to 2015" is an essential source of information and analysis on the global cystic fibrosis (CF) market. The report identifies the key trends shaping and driving the global CF market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global CF sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Scope
The scope of the report includes:
-Annualized global cystic fibrosis market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
-Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
-Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action include antibiotics and anti-infective agents, Ion transport modulators, anti-inflammatory agents, Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators, Nutritional supplements and Pancreatic Enzyme Replacement Therapy (PERT) classes of drugs.
-Analysis of the current and future market competition in the global CF market. Key market players covered are Cystic Fibrosis Foundation Therapeutics, Inc (CFFT), Pharmaxis, Gilead Sciences, Vertex Pharma, AstraZeneca and Pari Pharma.
-Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
-Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with cystic fibrosis.

Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
-Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
-Develop business strategies by understanding the trends shaping and driving the global cystic fibrosis market.
-Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global CF market in future.
-Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-Identify emerging players with potentially strong product portfolio and create effective   counter-strategies to gain competitive advantage.
-Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
-What's the next big thing in the global cystic fibrosis market landscape? -Identify, understand and capitalize.



Table of Contents
1 Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Global Cystic Fibrosis Market: Market Characterization 6
2.1 Overview 6
2.2 Cystic Fibrosis Market Size 6
2.3 Cystic Fibrosis Market Forecast and CAGR 6
2.4 Drivers and Barriers for Cystic Fibrosis Market 7
Drivers for Cystic Fibrosis Market 7
Barriers for Cystic Fibrosis Market 7
2.5 Opportunity and Unmet Need 7
2.6 Key Takeaway 9
3 Global Cystic Fibrosis Market: Competitive Assessment 10
3.1 Overview 10
3.2 Strategic Competitor Assessment 10
3.3 Product Profile for the Major Marketed Products in Cystic Fibrosis Market 11
Tobi (Tobramycin Inhalation Solution, USP) 11
Pulmozyme (Dornase Alfa) 12
Zenpep (Pancrelipase capsules) 13
3.4 Key Takeaway 14
4 Global Cystic Fibrosis Market: Pipeline Assessment 15
4.1 Overview 15
4.2 Strategic Pipeline Assessment 15
Technology Trends Analytic Framework 15  
4.3 Cystic Fibrosis Therapeutics-Promising Drugs under Clinical Development 17
4.4 Molecule Profile for Promising Drugs under Clinical Development 17
Cayston (Aztreonam lysine) 17
Denufosol Tetrasodium Inhalation Solution (INS37217) 19
VX-770 19
Bronchitol 20
Ataluren (PTC-124) 21
4.5 Cystic Fibrosis Therapeutics Market-Clinical Pipeline by Mechanism of Action 22
4.6 Cystic Fibrosis Pipeline-Pipeline by Clinical Phases of Development 22
Cystic Fibrosis Therapeutics-Regulatory and Phase III Clinical Pipeline 23
Cystic Fibrosis Therapeutics-Phase II Clinical Pipeline 24
Cystic Fibrosis Therapeutics-Phase I Clinical Pipeline 26
Cystic Fibrosis Therapeutics-Preclinical Pipeline 27
4.7 Discontinued/Suspended Drugs for Cystic Fibrosis 27
4.8 Key Takeaway 27
5 Global Cystic Fibrosis Market: Implications for Future Market Competition 29
6 Global Cystic Fibrosis Market: Future Players in Cystic Fibrosis Market 30
6.1 Introduction 30
6.2 Cystic Fibrosis Foundation Therapeutics, Inc. 30
Overview 30
Cystic Fibrosis Portfolio 31
Cystic Fibrosis Product Portfolio 33
6.3 Pharmaxis Ltd 34
Overview 34
Respiratory Portfolio 34
Cystic Fibrosis Product Portfolio 34
6.4 Gilead Sciences, Inc 35
Respiratory Portfolio 35
Cystic Fibrosis Product Portfolio 35
6.5 Vertex Pharmaceuticals, Inc 36
Overview 36
Respiratory Portfolio 37
Cystic Fibrosis Product Portfolio 37
6.6 AstraZeneca 38
Overview 38
Respiratory Portfolio 38
Cystic Fibrosis Product Portfolio 39
6.7 PARI Pharma 39
Overview 39
Respiratory Portfolio 39
Cystic Fibrosis Product Portfolio 39
7 Global Cystic Fibrosis Market: Appendix 40
7.1 Market Definitions 40
7.2 Abbreviations 40
7.3 Research Methodology 41
Coverage 41
Secondary Research 42
Forecasting 42
Primary Research 45
Expert Panel validation 45
7.4 Contact Us 45
7.5 Disclaimer 45
7.6 Sources 46

List of Tables
1.1 List of Tables
Table 1: Global Cystic Fibrosis Therapeutics Market, Revenue ($m), 2000-2008 7
Table 2: Global Cystic Fibrosis Therapeutics Market, Revenue ($m), 2009-2015 7
Table 3: Major Marketed Products Comparison in Cystic Fibrosis  Market, 2009 14
Table 4: Cystic Fibrosis Therapeutics-Most Promising Drugs Under Clinical Development, 2009 17
Table 5: Cystic Fibrosis Therapeutics-Phase III Clinical Pipeline, 2009 23
Table 6: Cystic Fibrosis Therapeutics-Phase II Clinical Pipeline, 2009 24
Table 7: Cystic Fibrosis  Therapeutics-Phase I Clinical Pipeline, 2009 26
Table 8: Cystic Fibrosis  Therapeutics-Preclinical Pipeline, 2009 27
Table 9: List of Discontinued Drugs for Cystic Fibrosis, 2009 27
Table 10: CFFT-Cystic Fibrosis Marketed Products, 2009 31
Table 11: CFFT-Cystic Fibrosis Pipeline Products, 2009 32
Table 12: Pharmaxis Ltd-Respiratory Marketed Product, 2009 34
Table 13: Pharmaxis Ltd-Respiratory Pipeline Products, 2009 34
Table 14: Gilead Sciences, Inc-Respiratory Pipeline Products, 2009 35
Table 15: Vertex Pharmaceuticals Inc-Respiratory Pipeline Products, 2009 37
Table 16: AstraZeneca-Respiratory Marketed Products, 2009 38
Table 17: AstraZeneca-Respiratory Pipeline Products, 2009 38
Table 18:  Pari Pharma-Respiratory Marketed Products, 2009 39
Table 19: Pari Pharma-Respiratory Pipeline Products, 2009 39

List of Figures
1.2 List of Figures
Figure 1: Global Cystic Fibrosis Market, Revenue ($m), 2000-2015 6
Figure 2: Opportunity and Unmet Need, 2009 8
Figure 3: Strategic Competitor Assessment of the Major Marketed Products in Cystic Fibrosis, 2009 10
Figure 4: Technology Trends Analytic Framework of the Cystic Fibrosis Pipeline, 2009 15
Figure 5: Technology Trends Analytic Framework of the Cystic Fibrosis Pipeline-Description, 2009 16
......

# # #

ChinaCCM.com is China's leading industry consultancy expert offering industry intelligence and research solution, ChinaCCM Market Research Centre is a research division focusing on professional market survey and industry research.